Related references
Note: Only part of the references are listed.How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective
Vikas Prasad et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India
Madhav Danthala et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors
Francesco Fiore et al.
ENDOCRINE (2014)
Significant impact of transient deterioration of renal function on dosimetry in PRRT
Sofie Van Binnebeek et al.
ANNALS OF NUCLEAR MEDICINE (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
[123I]Iodometomidate Imaging in Adrenocortical Carcinoma
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Functional Characterization of Adrenal Lesions Using [123I] IMTO-SPECT/CT
Stefanie Hahner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study
Boris Decarolis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Amir Sabet et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors Introduction to the International Working Group Report
Andrew Kennedy et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours
Anders Sundin
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma
Stefanie Hahner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy
Giampiero Giovacchini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Jolanta Kunikowska et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
Christoph J. Auernhammer et al.
GUT (2011)
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
Philip Elsinga et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
Irene Virgolini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
Valentina Ambrosini et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Flavio Forrer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
Dik J. Kwekkeboom et al.
NEUROENDOCRINOLOGY (2009)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor
Tapas Das et al.
APPLIED RADIATION AND ISOTOPES (2007)
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
Martijn Van Essen et al.
ACTA ONCOLOGICA (2007)
Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro
Jenny Oddstig et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors - Variables affecting response rates and survival
S Gupta et al.
CANCER (2005)
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
A Helisch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours
WW de Herder et al.
ENDOCRINE-RELATED CANCER (2003)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
LB Anthony et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Share Paper
